Woo Wongi, Park Brandon, Ahadi Awranoos, Chung Liam Il-Young, Jung Chan Mi, Bharat Ankit, Chae Young Kwang
Department of Internal Medicine, Dignity Health St. Joseph Medical Center Stockton, Stockton, California, USA.
University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
J Surg Oncol. 2025 May;131(6):1035-1043. doi: 10.1002/jso.28033. Epub 2024 Dec 15.
Due to heterogeneous characteristics of primary cancers, the efficacy of pulmonary metastasectomy (PM) in nonprimary lung cancers has not been investigated. This study aims to investigate the clinical outcomes of PM for non-primary lung cancer.
A systematic search for meta-analyses on PM for nonprimary lung cancers was conducted, encompassing publications up to January 3, 2024. This included seven primary cancers: renal cell, breast, adrenocortical, head and neck cancers, melanoma, germ cell tumors, and sarcoma. Overall survival and recurrence rates post-PM were assessed using random-effect models.
This study included 16 systematic-review articles and 101 individual studies, involving 10 277 patients who underwent PM for nonprimary lung cancer. About half of the patients (47.1%) presented with multiple metastasis, and complete resection achieved in 87.2% [95% CI: 83.0-90.8]. The pooled 5-year overall survival rate post-PM was 41.2% [95%CI: 37.1%-45.4%]. Patients with germ cell tumors demonstrated higher survival rate (p < 0.05), while melanoma exhibited the worst outcome (p < 0.05). During follow-up, 57.6% [95% CI: 46.4-68.1] had recurrence; 48% of them had intrathoracic-only recurrence.
This study underscores the survival benefits associated with PM. Overall survival rates following PM did not differ based on primary cancer types. These findings highlight the importance of recognizing and incorporating PM into clinical practice when appropriate.
由于原发性癌症的异质性,尚未对非原发性肺癌行肺转移瘤切除术(PM)的疗效进行研究。本研究旨在探讨非原发性肺癌行PM的临床结局。
对截至2024年1月3日关于非原发性肺癌行PM的荟萃分析进行系统检索。这包括七种原发性癌症:肾细胞癌、乳腺癌、肾上腺皮质癌、头颈癌、黑色素瘤、生殖细胞肿瘤和肉瘤。采用随机效应模型评估PM后的总生存率和复发率。
本研究纳入16篇系统评价文章和101项个体研究,涉及10277例行非原发性肺癌PM的患者。约一半患者(47.1%)出现多发转移,87.2%[95%CI:83.0 - 90.8]实现了完全切除。PM后汇总的5年总生存率为41.2%[95%CI:37.1% - 45.4%]。生殖细胞肿瘤患者的生存率较高(p < 0.05),而黑色素瘤患者的预后最差(p < 0.05)。随访期间,57.6%[95%CI:46.4 - 68.1]出现复发;其中48%仅出现胸内复发。
本研究强调了PM带来的生存获益。PM后的总生存率不因原发性癌症类型而异。这些发现凸显了在适当的时候认识并将PM纳入临床实践的重要性。